ERBB2 and breast carcinoma: Luminal A is characterized by positive hormone receptor ER+, high expression PR+, negative HER2 (HER2–), and low expression of Ki67, and Luminal A accounts for 50%–60% of all breast cancer cases (De Abreu et al. 2013).